Cannabinoids as co-analgesics: review of clinical effectiveness
Canadian Agency for Drugs and Technologies in Health
Record ID 32011001158
English
Authors' recommendations:
In conclusion, the four identified studies suggest that the use of cannabinoids as co-analgesia in patients with non-neuropathic pain is effective. The patient populations included in the studies varied and included patients with cancer pain, non-cancer pain, rheumatoid arthritis, and acute postherpetic neuralgia. The studies also varied with type of cannabinoid used, the agents used for co-analgesia, and the outcome measurements. The information is limited, and thereforeuncertainty exists with regards to efficacy and adverse events, ideal patient population, dosage, and formulation which may be a consideration for decision-making. Research into a better understanding of patient populations which may benefit the most from an adjuvant cannabinoid and the required dosage combination for co-analgesics considering their adverse-event profile may be needed to inform decision-making.
Details
Project Status:
Completed
Year Published:
2010
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Analgesics
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.